Medical device firm Stent Tek said today it closed an undisclosed Series A financing round to support the development of its ePath AVF minimally invasive catheter technology.
The ePath AVF device is designed for vascular access as an alternative to surgical fistulas for hemodialysis patients.
Money in the round came from institutional investors Julz and Deepbridge Capital, the London-based company said.
Stent Tek has previously received $1.6 million (GBP £1.2 million) in grant funding from the National Institute of Health Research, Innovate UK and the Royal Academy of Engineering Enterprise Hub.
“I was thoroughly impressed of the discipline shown by the team and its proactive handling of issues that startups invariably face in developing medical devices that require high regulatory compliance. We are delighted to follow our initial seed investment and look forward to working with the Stent Tek team,” Deepbridge Capital’s Savvas Neophytou said in a prepared statement.
The company said it has validated the device’s core functionality in in-vivo models, and hopes to complete pre-clinical trials of the system by the 4th quarter of this year.
“We are delighted with the investment from Deepbridge Capital and Julz. They bring valuable knowledge, well-respected global networks and synergy to Stent Tek’s efforts to be the leading provider of a minimally invasive alternative to surgical fistulas for vascular access. With our combined experience and the investors’ valuable inputs into our strategic developmental efforts, Stent Tek will gain momentum in translating clinical advancements to market readiness,” co-founder and CEO Sorin Popa said in a press release.